Equality impact assessment – Guidance development

HST - Elosulfase alfa for treating mucopolysaccharidosis type IVA [ID744]

The impact on equality has been assessed during this evaluation according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

   Not applicable – no issues raised during scoping

2. Have any other potential equality issues been raised in the submissions, expert statements or independent academic report, and, if so, how has the Committee addressed these?

   A clinical expert noted that people who are no longer mobile or who have severe disabilities may not benefit from elosulfase alfa; if elosulfase alfa were not recommended for this group, this may be considered discrimination on the basis of established physical disabilities.

   This was not applicable in light of the Committee's recommendations – the Committee was minded not to recommend elosulfase alfa for treating mucopolysaccharidosis type IVa (MPS IVa).
3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

Not applicable – no further issues have been identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE’s obligations to promote equality?

Not applicable.

7. Have the Committee’s considerations of equality issues been described in the evaluation consultation document, and, if so, where?

Not applicable.

Approved by Associate Director (name): ...........................................

Date: [xx/xx/year]
Highly specialised technologies: Guidance development
Equality impact assessment for the highly specialised technologies evaluation of Elosulfase alfa for treating mucopolysaccharidosis type IVA [ID 744]
Issue date: December 2015
## Final evaluation determination

(when an ECD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

   No.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

   Not applicable.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

   Not applicable.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE’s obligations to promote equality?

   Not applicable.

5. Have the Committee’s considerations of equality issues been
No equality issues were discussed by the Committee. This is described in the summary table.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 4/12/2015